Head to head
Aclaris Therapeutics vs Vertex Pharmaceuticals
Side-by-side on the measures that matter, with a plain-English read. Full detail: ACRS · VRTX
ACRS
Aclaris Therapeutics
3.38-0.71%
1-year price shape — +85% over the period
Quant Rating B · 79/100
vs
VRTX
Vertex Pharmaceuticals
506.64+0.20%
1-year price shape — +23% over the period
Quant Rating C · 67/100
1-year performance, rebased to 100
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
| ACRS | VRTX | |
|---|---|---|
| Snapshot | ||
| Sector | Biotechnology | Biotechnology |
| Last price | 3.38 | 506.64 |
| Change today | -0.71% | +0.20% |
| 1-year return | +84.8% | +23.2% |
| Market cap | $496.94M | $128.41B |
| 52-week range | 1.74 – 6.60 | 402.58 – 560.25 |
| Valuation | ||
| P/E (TTM) | -5.82 | 29.51 |
| P/E percentile, own 5-yr range | 49th | 74th |
| P/B | 3.99 | 6.34 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | -0.53 | 15.32 |
| Net profit (TTM) | $-78.02M | $3.88B |
| Revenue (TTM) | $8.22M | $12.59B |
| Revenue growth (YoY) | -8.3% | +12.5% |
| Gross margin | 12.9% | 86.0% |
| Operating margin | -1040.4% | 37.9% |
| Net margin | -921.5% | 35.0% |
| Free cash flow (TTM) | $-62.18M | $3.80B |
| Ownership & sentiment | ||
| Institutional ownership | 84.1% | 97.2% |
| Insider activity (12mo) | 40 buy / 10 sell | 25 buy / 25 sell |
| Short interest (% of float) | 10.9% | 1.9% |
| Analyst consensus | 100% buy (5) | 88% buy / 8% hold / 4% sell (24) |
| Analyst price target | $12 (+255%) | $580 (+15%) |
| StockVane view | ||
| StockVane Quant Rating | B (79) | C (67) |
| Company | ||
| Employees | 73 | 6,400 |
| Founded | 2012 | 1989 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.